Privacy Statement   Terms & Conditions   Sitemap  
  Diseases   Research   About us  
Clinical Development Product Pipeline How Vaccines work Glossary Events
 
Product Pipeline

  MVA (Modified Vaccinia Ankara)

Together with Acambis, Baxter is developing a third generation smallpox vaccine based on the strain Modified Vaccinia Ankara (MVA). MVA is an attenuated form of the current generation of smallpox vaccines and, as such, is expected to allow the safe inoculation of “at risk” individuals with weakened immune systems, who could otherwise not be vaccinated against smallpox.

 » Printversion

 
 
  » find


 

Baxter initiates clinical study with cell-based candidate H5N1 Pandemic Vaccine
» read more

Baxter to participate in development of cell-based vaccines for U.S. Department of Health and Human Services
» read more

Baxter Receives Contract From National Health Service in United Kingdom to Produce Stockpile of H5N1 Flu Vaccine
» read more

 
Baxter Vaccines Industriestrasse 67, A-1221 Wien, Tel: +43-1-20100,